Ptc Therapeutics (PTCT) Other Accumulated Expenses (2012 - 2026)

Ptc Therapeutics' Other Accumulated Expenses history runs 15 years deep, the most recent figure standing at $13.6 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 86.69% year-over-year to $13.6 million in Q1 2026; TTM through Mar 2026 was $13.6 million, a 86.69% increase from a year earlier, with the FY2025 full-year figure at $16.5 million, up 83.99% from the prior year.
• Other Accumulated Expenses retreated to $13.6 million in Q1 2026 per PTCT's latest filing, from $16.5 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $74.1 million in Q4 2023 and bottomed at $1.3 million in Q3 2022.
• The 5-year median for Other Accumulated Expenses is $15.1 million (2024), against an average of $23.7 million.
• Across the five-year window, Other Accumulated Expenses soared 3870.05% in 2023 and slumped 87.92% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $12.1 million in 2022, then soared by 514.82% to $74.1 million in 2023, then slumped by 87.92% to $9.0 million in 2024, then jumped by 83.99% to $16.5 million in 2025, then declined by 17.21% to $13.6 million in 2026.
• Per Business Quant, the three latest PTCT Other Accumulated Expenses figures stand at $13.6 million (Q1 2026), $16.5 million (Q4 2025), and $5.1 million (Q3 2025).